Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CDXC Stock Forecast 2026-2027
$3.86
Current Price
$298.49M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CDXC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CDXC Price Momentum
0.0%
1 Week Change
-7.4%
1 Month Change
-71.3%
1 Year Change
-39.3%
Year-to-Date Change
-73.7%
From 52W High of $14.69
+8.3%
From 52W Low of $3.57
📊 TOP ANALYST CALLS
Did CDXC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ChromaDex is one of their latest high-conviction picks.
Latest CDXC Stock Price Targets & Analyst Predictions
CDXC has shown a year-to-date change of -39.3% and a 1-year change of -71.3%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CDXC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CDXC Analyst Ratings
5
Buy
0
Hold
0
Sell
CDXC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $3.86
Latest CDXC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CDXC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 17, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $11.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $11.00 |
| Mar 5, 2025 | Ladenburg Thalmann | Jeffrey Cohen | Buy | Maintains | $8.10 |
| Nov 6, 2024 | Roth MKM | Sean McGowan | Buy | Maintains | $8.00 |
| Nov 4, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $8.00 |
| Aug 9, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
| Jul 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
| Jun 12, 2024 | Roth MKM | Sean McGowan | Buy | Maintains | $6.00 |
| May 9, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
| Apr 9, 2024 | Roth MKM | Sean McGowan | Buy | Maintains | $6.00 |
| Mar 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $6.00 |
| Aug 10, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $5.00 |
| Jun 5, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $5.00 |
| Mar 13, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $5.00 |
| Feb 1, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $5.50 |
| Aug 29, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $5.50 |
| Aug 16, 2022 | Oppenheimer | Brian Nagel | Perform | Downgrade | $N/A |
| Aug 11, 2022 | B. Riley Securities | Jeff Van Sinderen | Neutral | Downgrade | $2.40 |
Niagen Bioscience Inc. (CDXC) Competitors
The following stocks are similar to ChromaDex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Niagen Bioscience Inc. (CDXC) Financial Data
Niagen Bioscience Inc. has a market capitalization of $298.49M with a P/E ratio of 71.5x. The company generates $99.60M in trailing twelve-month revenue with a 61.8% profit margin.
Revenue growth is +4.7% quarter-over-quarter, while maintaining an operating margin of +7.8% and return on equity of +18.5%.
Valuation Metrics
Market Cap
$298.49M
Enterprise Value
$256.64M
P/E Ratio
71.5x
PEG Ratio
-0.1x
Price/Sales
3.0x
Growth & Margins
Revenue Growth (YoY)
+4.7%
Gross Margin
+63.4%
Operating Margin
+7.8%
Net Margin
+61.8%
EPS Growth
+37.6%
Financial Health
Cash/Price Ratio
N/A
Current Ratio
3.7x
Debt/Equity
0.1x
ROE
+18.5%
ROA
+12.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Niagen Bioscience Inc. (CDXC) Business Model
About Niagen Bioscience Inc.
What They Do
Develops NAD+ science for cellular health.
Business Model
The company generates revenue by commercializing its proprietary Niagen platform, which offers NAD+-boosting ingredients like nicotinamide riboside (NR) through products such as Tru Niagen and Niagen Plus. It also provides quality assurance materials and supplies NAD+ precursors to researchers, creating multiple income streams within health and wellness sectors.
Additional Information
Located in Los Angeles, Niagen Bioscience Inc. operates ISO-accredited labs and emphasizes science-backed innovation and regulatory compliance in its product offerings. The company targets various markets, including dietary supplements, food, beverages, skin care, and pharmaceuticals, positioning itself as a leader in NAD+ research and application.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
117
CEO
Mr. Robert N. Fried
Country
United States
IPO Year
2008
Website
www.niagenbioscience.comNiagen Bioscience Inc. (CDXC) Latest News & Analysis
Latest News
Quick Summary
Niagen Bioscience, Inc. (formerly ChromaDex Corp.) has changed its name and will trade under the new Nasdaq symbol "NAGE" starting March 19, 2025.
Why It Matters
The name change to Niagen Bioscience and new Nasdaq symbol NAGE may enhance brand recognition and investor interest, potentially impacting stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
ChromaDex Corp. (NASDAQ:CDXC) will change its name to Niagen Bioscience, Inc., and its trading symbol to "NAGE" effective March 19, 2025. Further updates will follow.
Why It Matters
ChromaDex's rebranding to Niagen Bioscience and new Nasdaq symbol may attract investor interest, reflecting a strategic shift and potential growth in the healthy aging sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
ChromaDex Corp. (NASDAQ: CDXC) will participate in the 37th Annual ROTH Conference on March 17, featuring CEO Rob Fried on the Longevity and Supplementation Panel. Livestream available.
Why It Matters
ChromaDex's participation in a prominent conference highlights its commitment to healthy aging and could attract investor interest, potentially impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
ChromaDex Corporation reports a 37.41% revenue increase and $7.2 million net income, driven by Niagen. However, it faces supply chain and regulatory challenges that may affect growth.
Why It Matters
ChromaDex's strong revenue growth and profitability highlight its market potential, but execution risks and external challenges may affect future performance and investor confidence.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
ChromaDex Corporation (NASDAQ:CDXC) will host its Q4 2024 earnings conference call on March 4, 2025, at 4:30 PM ET, featuring key executives and analysts.
Why It Matters
The earnings call provides insights into ChromaDex’s financial performance and strategic direction, influencing investor perceptions and potential stock movements.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
ChromaDex Corp. (NASDAQ: CDXC) reported Q4 2024 net sales of $29.1M, with Tru Niagen® sales up 37%. Gross margin improved to 62.5%, and G&A expenses decreased by $4.4M.
Why It Matters
ChromaDex's strong Q4 performance, highlighted by a 37% sales increase and improved margins, signals growth potential, making it an attractive option for investors seeking opportunities in health products.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CDXC Stock
What is Niagen Bioscience Inc.'s (CDXC) stock forecast for 2026?
Analyst forecasts for Niagen Bioscience Inc. (CDXC) are not currently available. The stock is trading at $3.86.
Is CDXC stock a good investment in 2026?
According to current analyst ratings, CDXC has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.86. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CDXC stock?
Price predictions from Wall Street analysts for CDXC are not currently available. The stock is trading at $3.86.
What is Niagen Bioscience Inc.'s business model?
The company generates revenue by commercializing its proprietary Niagen platform, which offers NAD+-boosting ingredients like nicotinamide riboside (NR) through products such as Tru Niagen and Niagen Plus. It also provides quality assurance materials and supplies NAD+ precursors to researchers, creating multiple income streams within health and wellness sectors.
What is the highest forecasted price for CDXC Niagen Bioscience Inc.?
Price targets from Wall Street analysts for CDXC are not currently available. The stock is trading at $3.86.
What is the lowest forecasted price for CDXC Niagen Bioscience Inc.?
Price targets from Wall Street analysts for CDXC are not currently available. The stock is trading at $3.86.
What is the overall CDXC consensus from analysts for Niagen Bioscience Inc.?
The overall analyst consensus for CDXC is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are CDXC stock price projections?
Stock price projections, including those for Niagen Bioscience Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 11:36 AM UTC